Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGI226 in Achilles Tendinopathy
NCT05592990Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 3
01
Overview
A Phase 2 trial of NGI226 in Achilles tendinopathy, sponsored by Novartis. Started Jun 2023; status: completed.
02
Drugs
NGI226
03
Conditions
Achilles tendinopathy
Beyond the preview
Go deeper on NCT05592990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05592990.